Zheng et al., 2020 - Google Patents
Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer/T cell lymphomaZheng et al., 2020
View HTML- Document ID
- 6711121130780407626
- Author
- Zheng M
- Yu L
- Hu J
- Zhang Z
- Wang H
- Lu D
- Tang X
- Huang J
- Zhong K
- Wang Z
- Li Y
- Guo G
- Liu S
- Tong A
- Yang H
- Publication year
- Publication venue
- Translational Oncology
External Links
Snippet
Extranodal nasal natural killer (NK)/T cell lymphoma (ENKTCL) is a rare but highly aggressive subtype of non-Hodgkin lymphoma (NHL). Nevertheless, despite extensive research, the estimated 5-year overall survival of affected patients remains low. Therefore …
- 238000009169 immunotherapy 0 title abstract description 16
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer/T cell lymphoma | |
| AU2023278069B2 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| US20230250150A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| Yang et al. | Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer | |
| US20210038646A1 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
| Dai et al. | 4-1BB signaling boosts the anti-tumor activity of CD28-incorporated 2nd generation chimeric antigen receptor-modified T cells | |
| KR20230156808A (en) | Methods for modulation of car-t cells | |
| US20230167190A1 (en) | Chimeric antigen receptors targeting cd37 | |
| Dao et al. | Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody | |
| US20230322923A1 (en) | Methods and compositions relating to ex vivo culture and modulation of t cells | |
| US20190345218A1 (en) | Targeted t cells with cytotoxicity toward immunosuppressive cells | |
| CN115003698A (en) | anti-TCR antibody molecules and uses thereof | |
| Halim et al. | Engineering of an avidity-optimized CD19-specific parallel chimeric antigen receptor that delivers dual CD28 and 4-1BB co-stimulation | |
| Jin et al. | CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells | |
| CN112292140B (en) | Chimeric antigen receptor targeting CD37 and CD19 | |
| Yu et al. | Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma | |
| Pérez-Amill et al. | Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development | |
| Lu et al. | Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma | |
| JP2024542879A (en) | Multispecific binding sites comprising PD-1 and TGF-BRII binding domains | |
| Zhao et al. | Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing | |
| Stock et al. | Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma | |
| Brossart et al. | OPEN ACCESS EDITED AND REVIEWED BY | |
| Lin et al. | Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological malignancies | |
| Leong | Evaluation of Novel Antibodies for Chimeric Antigen Receptor T Cell Applications |